Sales of PROTONIX for the first nine months of 2007 totaled approximately $1.4 billion.
Wyeth will hold a conference call with research analysts at 8 a.m. on December 24, 2007 to discuss its plans going forward. Interested investors and others may listen to the call live or on a delayed basis through the Internet web cast, which may be accessed by visiting the Company's website at http://www.wyeth.com and clicking on the "Investor Relations" hyperlink.
About Wyeth Pharmaceuticals
Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.
Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release and on the related conference call
that are not historical facts are forward-looking statements based on
current expectations of future events and are subject to risks and
uncertainties that could cause actual results to differ materially from
those expressed or implied by such statements. In particular, we note that
the impact of the launch of generic pantoprazole tablets on sales of
PROTONIX cannot be predicte
|SOURCE Wyeth Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved